All In Biotech

Drug Trial Radar · NCT02482753

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE)

Last checked: Nov 20, 2026Latest source record: Jan 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

365

Actual

Start

Jul 2015

Primary completion

Mar 2018

Study completion Feb 2021

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Jun 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.

Conditions

  • Breast Cancer

Interventions

  • ChidamideDrug

    30 mg, administered orally twice per week (BIW)

  • exemestaneDrug

    25 mg, PO daily

  • placeboDrug

    Administered orally twice per week (BIW)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival (PFS), double-blinded periodTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
  2. pharmacokinetic profiles of Chidamide, open-label periodTime frame: 0,1,2,4,8,12,24,48,72 hours after the first dose of Chidamide on day 2 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage
  3. pharmacokinetic profiles of exemestane, open-label periodTime frame: 0,1,2,4,8,12,24 hours after the first dose of exemestane on day 1 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage
  4. acetylation level of histone H3, open-label periodTime frame: pre-dose of Chidamide on day 2 at induced stage (4 days in total); pre-dose of Chidamide on day 1 of cycle 2 at combination treatment stage

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The 307th Hospital of Chinese people's Liberation Army

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Tumor Hospital of Hebei Province

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Jiangsu, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The Third Hospital of Nanchang

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Fudan University ZhongShan Hospital

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.